6 completed, 1 withdrawn. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Withdrawn 1 |
Follow Phentermine: new trials by email Literature Review of Phentermine trials Research Report on Phentermine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users Pitolisant, Placebos, Phentermine - Healthy, Drug Abuse | Phase 1 | Completed | Bioprojet | 43 | 2017-03-15 | 2017-11-13 |
| A Study to Evaluate Abuse Potential of Istradefylline Istradefylline, Phentermine 45 mg, Placebo - Drug Abuse | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 42 | 2016-01-01 | 2024-04-25 |
| FDA Approved Medication to Reduce Binge Eating and/or Purging Phentermine/Topiramate-First, Placebo - Binge Eating Disorder, Bulimia Nervosa | Phase 1 | Completed | Stanford University | 22 | 2015-10-30 | 2018-05-14 |
| Topiramate-Phentermine Combinations for Cocaine Dependence Cocaine, Placebo, Phentermine - Cocaine Use Disorder | Phase 1 | Completed | University of Kentucky | 38 | 2014-09-01 | 2019-11-27 |
| Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214 TC-5214, TC-5214 Placebo, Ketamine - Drug Abuse, Healthy | Phase 1 | Withdrawn | AstraZeneca | 2012-01-01 | 2012-03-22 | |
| A Study to Evaluate the Pharmacokinetics of VI-0521 Subjects With Renal Impairment Topirmate and Phentermine - Renal Impairment | Phase 1 | Completed | VIVUS LLC | 32 | 2008-10-01 | 2009-12-01 |
| Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults topiramate, phentermine - Obesity | Phase 1 | Completed | VIVUS LLC | 64 | 2007-07-01 | 2011-06-08 |
Substance-Related Disorders (3) · Binge-Eating Disorder (1) · Bulimia (1) · Bulimia Nervosa (1) · Obesity (1) · Renal Insufficiency (1)
VIVUS LLC (2) · AstraZeneca (1) · Bioprojet (1) · Kyowa Kirin Co., Ltd. (1) · Stanford University (1) · University of Kentucky (1)
United States (5) · Canada (1)
Brendan Smyth, MD (1) · Craig R Rush, Ph.D. (1) · Debra L Safer, MD (1) · Hans A Eriksson, MD (1) · Michael B. McDonnell, MD (1) · Pierre Geoffroy, MDCM, MSC, FCFP (1) · Sarah Adler, PsyD (1) · Shebani Sethi, MD (1) · Shiyin Yee, PhD (1) · Wesley W Day, PhD (1)
PMID 29038069, PMID 31626696, PMID 31721257
R01DA032254 (1)